Securities Code: 300289
Securities Abbreviation: Lideman
Announcement No.: 2026-044
Beijing Lideman Biochemical Co., Ltd.
Announcement on the Completion of Asset Transfer for Major Asset Restructuring
The Company and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
Beijing Lideman Biochemical Co., Ltd. (hereinafter referred to as the "Company," "Lideman," or "Listed Company") has acquired 235,040,700 shares of Beijing P-Star Xiangrui Biological Products Co., Ltd. (hereinafter referred to as "P-Star Xiangrui" or the "Target Company") held by Hainan Baimai Investment Co., Ltd., Hainan P-Star Baijia Hui Technology Development Co., Ltd., and Nanjing Baijiarui Enterprise Management Consulting Partnership (Limited Partnership) (collectively referred to as the "Counterparties") through cash payment (representing 61.50% of the issued shares of P-Star Xiangrui, hereinafter referred to as the "Transaction"). The Transaction does not constitute a related-party transaction but constitutes a major asset restructuring as stipulated by the "Administrative Measures for Major Asset Restructuring of Listed Companies." The Transaction does not involve the issuance of shares and will not lead to a change in the Company's control. As of the date of this announcement, the transfer of the assets involved in the Transaction has been completed.
I. Implementation of the Transaction
(I) Transfer of the Target Assets
The target assets of this Transaction are 235,040,700 shares of P-Star Xiangrui. As of the date of this announcement, the target assets have been transferred and registered in the Company's name, and a "Confirmation Letter of Securities Transfer Registration" has been obtained from China Securities Depository and Clearing Corporation Limited, confirming the completion of the asset delivery. Thus, the transfer procedures for the target assets of this Transaction have been completed. Following this transfer, the Company directly holds 235,040,700 shares of P-Star Xiangrui, and P-Star Xiangrui has become a controlling subsidiary of the Company.
(II) Payment of Transaction Consideration